Immunocore Holdings Ltd

Immunocore Holdings plc develops and commercializes immunomodulating medicines for cancer, infectious diseases, and autoimmune disease, operating in the United States, Europe, and internationally. Its product KIMMTRAK treats unresectable or metastatic uveal melanoma. The company's pipeline includes tebentafusp in Phase 3 for advanced cutaneous melanoma and adjuvant uveal melanoma, brenetafusp in Phase 3 for first-line advanced cutaneous melanoma and Phase 1/2 for various tumor types, IMC-R117C in Phase 1/2 for advanced solid tumors such as colorectal cancer, and IMC-P115C in Phase 1 for PRAME-expressing tumors. It also develops IMC-M113V and IMC-I109V in Phase 1 for potential functional cures of HIV and hepatitis B virus, respectively, plus IMC-S118AI and IMC-U120AI in pre-investigation for type 1 diabetes and atopic dermatitis. Founded in 1999, it is headquartered in Abingdon, United Kingdom.